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Abstract
Aims Concentrations of circulating B-type natriuretic peptides provide important prognostic information in heart failure
(HF) patients. We directly compared the prognostic performance of brain natriuretic peptide (BNP) versus N-termi-
nal-proBNP (NT-proBNP) measurements in a large population of HF patients at hospital discharge after an admission for
decompensated HF.
Methods and results BNP and NT-proBNP were measured in 563 stable HF patients before discharge. All patients were
followed for a fixed period of 18 months. The primary endpoint was time to first major event (HF hospitalisation or death).
Patients were in NYHA class II (47%) or III/IV (53%) at discharge and the mean age of the patients was 71± 11 years, 217
(39%) females, mean left ventricular ejection fraction was 0.32± 0.14 and 234 (42%) had an ischaemic aetiology of HF.
During the study, 236 patients (42%) reached the primary endpoint. Multivariate odds ratios of the primary endpoint for
doubling of baseline levels of BNP and NT-proBNP were 1.46 (95% CI 1.19–1.80, p< 0.001) and 1.45 (95% CI 1.18–1.78,
p< 0.001), respectively. The multivariable adjusted areas under the receiver-operating characteristic curve for prediction
of the primary endpoint for doubling of BNP and NT-proBNP were 0.69 and 0.68, respectively. Direct comparison of the
prognostic value of BNP and NT-proBNP did not reveal significant differences.
Conclusions BNP and NT-proBNP at discharge for hospitalisation for HF are powerful, and equally strong and independent
predictors of all-cause death and HF rehospitalisation.
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What’s new?
● In patients with decompensated heart failure (HF), both
B-type natriuretic peptides (BNP and NT-proBNP) are
equally strong and independent predictors of outcome
(HF rehospitalisation or death)
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● Both natriuretic peptides have comparable predictive ac-
curacy at hospital discharge for HF.
● Clinically relevant for disease monitoring in HF patients
treated with exogenous BNP or sacubitril/valsartan.
● Important for the selection of patients in trials and usage
of natriuretic peptides as endpoints.
Introduction
Hospitalisation for acute heart failure (HF) syndromes por-
tends a poor prognosis in patients with chronic HF [1].
Brain natriuretic peptides (BNP) and its equimolarly se-
creted amino-terminal fragment (NT-proBNP) are strong
independent predictors of mortality and cardiovascular
(CV) events in patients with heart failure (HF) [2–4].
Therefore, these biomarkers can help to identify patients at
high risk for premature death or HF (re)hospitalisation.
Although both natriuretic peptides are frequently used,
direct comparative studies on the prognostic value of BNP
and NT-proBNP are scarce. Since BNP and NT-proBNP
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differ with regard to their biological activity and half-life,
in vitro stability and clearance mechanisms, potential differ-
ences regarding their prognostic value may exist. In the Val-
HeFT study the prognostic values of BNP and NT-proBNP
were compared in patients with stable chronic HF and in
that study NT-proBNP was better in terms of predicting
outcome [5]. However, predicting outcome after hospital
discharge for worsening HF may be more difficult, but is
clinically relevant. In this condition, only the findings from
relatively small comparative studies are available [6–8].
Therefore, the purpose of our present study was to di-
rectly compare the prognostic performance of BNP versus
NT-pro-BNP measurements in a large population of HF pa-
tients at hospital discharge after an admission for decom-
pensated HF.
Methods
Patient population and study design
This analysis was performed as part of the Coordinating
study evaluating Outcomes of Advising and Counselling in
Heart Failure (COACH) study, a multicentre, randomised,
open trial with blinded endpoint evaluation, in which 1,023
patients were enrolled. It was designed to compare basic
support and intensive support in patients with chronic HF
to a control group receiving ‘usual’ care, as described in
detail before [9]. All patients had been admitted to hos-
pital with symptoms of HF, New York Heart Association
(NYHA) functional class II–IV. Patients were ±18 years of
age and had evidence of structural underlying heart disease,
as shown by cardiovascular imaging. Both patients with an
impaired and those with a preserved left ventricular ejection
fraction could participate. Before discharge from the hos-
pital (i. e. before inclusion into the study), patients had to
be stable on standard medication for HF, at the discretion
of the physician and if tolerated. After inclusion, all pa-
tients were followed for a fixed time period of 18 months.
Primary endpoints were time to death or rehospitalisation
for HF, and the number of days lost to death or hospitali-
sation. The Medical Ethics Committee approved the study
protocol and all patients provided written informed con-
sent. Institutional review board approval was given for all
17 participating Dutch centres. The primary results of the
COACH study have been published previously [10].
In the current analyses, we only investigated COACH
patients in whom measurements of plasma levels of both
BNP and NT-proBNP at hospital discharge for decompen-
sated chronic heart failure (baseline) were available. Of the
1,023 patients included in the COACH study, 563 patients
had both BNP and NT-proBNP plasma levels available.
The main reason for missing BNP and NT-proBNP data
was temporary unavailability of the necessary laboratory
facilities, usually in the starting phase of the study. Details
have been published previously [11]. We studied the pri-
mary endpoint, time to first major event (HF hospitalisation
or death).
Previously we reported specifically on the prognostic sig-
nificance of BNP (and NT-proBNP) in heart failure patients
with reduced and preserved left ventricular ejection fraction
(LVEF) (40% and >40%, respectively) who participated
in the COACH study [3]. In the current analyses we intro-
duced LVEF as a continuous variable.
Statistical analyses
Continuous variables with a normal distribution are ex-
pressed as means with standard deviation (SD). Nominal
variables are expressed as n (%). Levels of BNP and NT-
proBNP with a skewed distribution are given as medians
with interquartile range (IQR). Differences in continuous
variables were evaluated by Student’s t-test or Mann-Whit-
ney-U tests, depending on normality of data. Categorical
clinical variables were compared with the Fisher’s exact
test or chi-square test. To achieve a constant variance, na-
triuretic peptide values were logarithmically transformed.
BNP levels were correlated with NT-proBNP levels using
Spearman’s rank correlation coefficient.
The primary endpoint was time to first major event (HF
hospitalisation or death). To estimate the size of the ef-
fect, odds ratios (ORs) with 95% confidence intervals (CIs)
were calculated with the use of logistic regression models.
A stepwise approach was used.
Risk estimates should be interpreted as the relative risk
if values of BNP or NT-proBNP were doubled (e.g., from
10 to 20pg/ml). From logistic regression analysis the pre-
dictive values of BNP and NT-proBNP were determined
and the area under the receiver operating characteristics
(ROC) curves (AUC) for quantification of the predictive
accuracy were calculated. An ROC area of 0.5 signifies no
discriminatory value, while an area of 1.0 means perfect
discrimination for prediction of those with and without an
endpoint during follow-up.
Furthermore, a direct comparison of single levels in the
regression models in COACH patients was part of this anal-
ysis.
All reported probability values are two-tailed and
p< 0.05 was considered statistically significant. Analy-
ses were performed using STATA software (STATA version
10.0, College Station, Texas, USA).
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Table 1 Baseline characteristics of the study group at hospital
discharge
Study group (n= 563)
Female gender 217 (39%)
Age (years) 71± 11
NYHA class III or IVa 294 (53%)
LVEF 0.32± 0.14
Body mass index (kg/m2) 26± 5
Aetiology of heart failure
– Ischaemic heart disease 234 (42%)
– Non-ischaemic heart disease 329 (58%)
Previously hospitalised for HF 192 (34%)
Comorbidities
– Hypertension 249 (44%)
– Atrial fibrillation 258 (46%)
– Diabetes 167 (30%)
– Stroke 51 (9%)
– COPD 156 (28%)
Medication
– ACE-I and/or ARB 463 (82%)
– β-blockers 375 (67%)
– Diureticsb 538 (96%)
Laboratory values
– Haemoglobin (mmol/l) 8.2± 1.3
– eGFR (ml/min/1.73m2) 54± 20
– BNP (pg/ml)c 447 (196–906)
– NT-proBNP (pg/ml)c 2,528 (1289–5615)
SI conversion factors: To convert NT-proBNP to picomoles per
litre, divide by 8.46; BNP to picomoles per litre, divide by 3.47;
haemoglobin to grams per litre, divide by 0.62
All continuous variables are presented as mean± SD
ACE-I angiotensin-converting enzyme inhibitor, ARB angiotensin
receptor blocker, BNP brain natriuretic peptide, COPD chronic
obstructive pulmonary disease, eGFR estimated glomerular filtration
rate, HF heart failure, LVEF left ventricular ejection fraction,
NT-proBNP N-terminal prohormone B-type natriuretic peptide,
NYHA New York Heart Association
aNYHA class at hospital discharge
bIncludes loop diuretics, thiazides, and aldosterone antagonists
cA continuous variable is presented as median value (25th–75th
percentiles)
Results
Baseline characteristics and outcome
The study group at baseline comprised 563 HF patients:
217 (39%) females, the mean age of the patients was
71± 11 years. Patients were in NYHA class II (47%) or
III/IV (53%) at discharge. Both in the total cohort of
COACH (n= 1,023) and in our subgroup (n= 563), only
4% of HF patients were in NYHA class IV at hospital
discharge. Therefore, we clustered NYHA class III and IV
in the current analyses.
The mean LVEF was 0.32± 0.14 and 234 (42%) had
an ischaemic aetiology of HF. Mean estimated glomeru-
lar filtration rate (eGFR) was 54± 20ml/min/1.73m2. There
were no significant differences in baseline characteristics
between patients who participated in this study and in the
main COACH cohort. In Tab. 1 baseline characteristics of
the study group (n= 563) at hospital discharge are pre-
sented.
During the 18-month study, the combined endpoint oc-
curred in 236 patients (42%) of the whole population.
BNP, NT-proBNP and outcome
At hospital discharge after an admission for decompensated
HF, median (25th–75th percentiles) BNP and NT-proBNP
levels in the 563 study patients were 447 (196–906) and
2,528 (1,289–5,615) pg/ml, respectively (Tab. 1). We found
Fig. 1 Multivariable adjusted probability of outcome according to the
BNP level at hospital discharge (on a log transformed scale)
Fig. 2 Multivariable adjusted probability of outcome according to the
NT-proBNP level at hospital discharge (on a log transformed scale)
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a strong association between BNP and NT-proBNP con-
centrations (correlation coefficients 0.82, p< 0.001). BNP
at baseline was significantly (p< 0.05) related to: NYHA
class, LVEF, body mass index (BMI), and HF underlying
disease (ischaemic vs. non-ischaemic). NT-proBNP at base-
line was significantly related to age, NYHA class, LVEF,
BMI, HF underlying disease (ischaemic vs. non-ischaemic),
haemoglobin and eGFR.
The baseline median BNP and NT-proBNP levels were
higher in patients (n= 236, 42%) who reached the primary
endpoint compared with those (n= 337, 58%) who remained
free of this endpoint: 559 vs. 352pg/ml, p< 0.001; and
3,396 vs. 2,011pg/ml, p< 0.001, respectively.
The multivariable adjusted probability for event-free sur-
vival and for the separate endpoints (HF hospitalisation and
all-cause death) according to the baseline BNP and NT-
proBNP levels, respectively, are depicted in Figs. 1 and 2.
Prognostic value of a single predischarge
measurement of BNP and NT-proBNP
Unadjusted, age- and gender-adjusted and multivariate ORs
of the primary endpoint for doubling of baseline levels of
BNP and NT-proBNP are presented in Tables 2 and 3.
Multivariate ORs (adjusted for age, NYHA class, LVEF,
BMI, HF underlying disease (ischaemic vs. non-ischaemic),
and eGFR) were 1.46 (95% CI 1.19–1.80, p< 0.001) and
1.45 (95% CI 1.18–1.78, p< 0.001), respectively for BNP
and NT-proBNP. In addition, both BNP and NT-proBNP
were independent predictors of the separate endpoints of
HF hospitalisation and all-cause death.
Table 2 Odds ratios for outcome according to doubling of B-type na-
triuretic peptide (BNP) at hospital discharge for heart failure
Odds ratio 95% CI P value
For primary endpoint
Unadjusted model 1.30 1.16–1.45 <0.001
Model 1 1.29 1.15–1.45 <0.001
Model 2 1.46 1.19–1.80 <0.001
For HF hospitalisation
Unadjusted model 1.24 1.09–1.41 <0.001
Model 1 1.25 1.09–1.41 <0.001
Model 2 1.42 1.20–1.68 <0.001
For all-cause death
Unadjusted model 1.41 1.20–1.66 <0.001
Model 1 1.40 1.19–1.66 <0.001
Model 2 1.37 1.12–1.69 0.003
Model 1: Age- and gender-adjusted model
Model 2: Multivariate model adjusted for significant covariates: age,
NYHA class, LVEF, BMI, HF underlying disease (ischaemic vs.
non-ischaemic), and eGFR
Table 3 Odds ratios for outcome according to doubling of N-terminal
pro-B-type natriuretic peptide (NT-proBNP) at hospital discharge for
heart failure
Odds ratio 95% CI P value
For primary endpoint
Unadjusted model 1.34 1.20–1.49 <0.001
Model 1 1.31 1.17–1.46 <0.001
Model 2 1.45 1.18–1.78 <0.001
For HF hospitalisation
Unadjusted model 1.23 1.10–1.40 <0.001
Model 1 1.22 1.08–1.38 <0.001
Model 2 1.33 1.13–1.56 <0.001
For all-cause death
Unadjusted model 1.55 1.33–1.82 <0.001
Model 1 1.50 1.28–1.76 <0.001
Model 2 1.45 1.17–1.78 <0.001
Model 1: Age and gender adjusted model
Model 2: Multivariate model adjusted for significant covariates: age,
NYHA class, LVEF, BMI, HF underlying disease (ischaemic vs.
non-ischaemic), and eGFR
Fig. 3 Receiver operating characteristics (ROC) curves (multivariable
adjusted) of discharge levels of BNP and NT-proBNP levels in predict-
ing hospitalisation for HF or death, both at 18 months
Predictive accuracy of BNP versus NT-proBNP
The areas under the ROC curve for prediction of the primary
endpoint, calculated for each doubling of BNP and NT-
proBNP, were 0.69 and 0.68 respectively.
The corresponding, multivariable adjusted ROC curves
for each doubling of BNP and NT-proBNP are plotted in
Fig. 3. There were no significant differences in AUC be-
tween BNP and NT-proBNP.
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Discussion
The main finding of the present study is that BNP and NT-
proBNP are equally strong and independent predictors of
outcome at hospital discharge. Direct comparison of the
predictive accuracy of BNP and NT-proBNP did not reveal
significant differences.
Rational use of these peptides is currently recommended
in patients with HF in several clinical settings: on admission
for decompensated heart failure, after a major treatment ef-
fect, at hospital discharge when euvolaemia is reached, and
during ambulatory follow-up [2, 12]. A single measurement
of a B-type natriuretic peptide provides strong and indepen-
dent prognostic information in patients with heart failure.
Previously, we observed in the COACH study that BNP
levels are lower in patients with HF with preserved ejection
fraction (HFpEF) than in patients with HF with reduced
ejection fraction (HFrEF), but for a given BNP level, the
prognosis in patients with HFpEF is as poor as in those
with HFrEF [3]. Patients with HFpEF were older, more
often female, and had a higher systolic blood pressure and
body mass index, and haemoglobin levels were lower than
in those with HFrEF.
Inclusion of BNP or NT-proBNP concentrations in the
diagnostic algorithm of HF is important both in clinical
decision making and for proper design of trials. In concor-
dance with proposed pathophysiological concepts, our re-
cent analyses of multiple biomarkers from COACH showed
that in HFpEF patients, inflammation and angiogenesis-me-
diated interactions were predominant, while stretch-medi-
ated interactions were found in HFrEF [2, 13–16].
Interestingly, in HFpEF patients with low BNP
(<100pg/ml) or low NT-proBNP (<300pg/ml), quality of
life, heart failure-related symptoms and clinical outcomes
were similar to those with elevated BNP levels [17].
Furthermore, we reported on the added value of a diverse
group of 29 biomarkers on top of a clinical risk model in
COACH with and without NT-proBNP. Low risk was de-
fined as a biomarker cut-off at the 10th percentile associated
with high positive predictive value for 30-day and 180-day
mortality and HF rehospitalisation [18].
HF symptom relief and euvolaemia reached at hospital
discharge is an important point of time for measurement of
BNP or NT-proBNP. Their concentrations may serve as tar-
gets for optimal fluid status or markers of disease evolution
during follow-up in addition to clinical parameters, and in
biomarker-guided management in HFrEF [19].
BNP versus NT-proBNP in heart failure
Plasma levels of the biological active BNP and inactive
N-terminal fragment of BNP are closely correlated with
each other in HF patients, as confirmed by the results of our
study. The Valsartan Heart Failure Trial (Val-HeFT) study
group provided a direct comparison of the prognostic value
of BNP and NT-proBNP in 3,916 patients with chronic and
stable HF [5]. They found that both peptides were powerful
independent markers of outcome in HF, but NT-proBNP
was superior to BNP in predicting mortality and morbidity
or hospitalisation for HF. In 164 patients (99% men) hospi-
talised for decompensated HF, Waldo and coworkers found
that admission and discharge NT-proBNP (AUC 0.788 and
AUC 0.834) had superior prognostic power for all-cause
mortality within 90 days post-discharge, when compared
with BNP (AUC 0.644, p< 0.01 and AUC 0.709, p< 0.01)
[6]. Also in a small study, 171 patients with acute HF,
Noveanu and coworkers reported that predischarge levels of
BNP and NT-proBNP reliably predicted one-year mortality
(AUC 0.78 and 0.77 respectively); however, prediction of
one-year HF readmission was poor for both markers [7]. In
a subgroup analysis of 306 patients with acute HF (FINN-
AKVA cohort), both BNP and NT-proBNP failed to im-
prove prediction of 5-year survival [8]. In 563 patients, we
found that the prognostic performance (all-cause mortality
or HF hospitalisation during 18 months) of BNP and NT-
proBNP at the time of hospital discharge were comparable.
From other studies, it became apparent that patient- and
assay-related factors influence both BNP and NT-proBNP
concentrations [2, 20]. In head-to-head comparisons, dis-
tinct discrepancies in individual patients demonstrated that
both markers are clinically not completely equivalent [7–9,
21, 22]. Furthermore, BNP was found to be more sensi-
tive to rapid haemodynamic changes in acute heart fail-
ure than NT-proBNP [8, 23]. Importantly, monitoring by
means of BNP testing of chronic heart failure patients on
exogenous administered BNP or guideline-recommended
sacubitril-valsartan treatment, may be impaired, in contrast
to NT-proBNP, which is not a substrate for neprilysin in-
hibition [24]. So, these issues should be taken into ac-
count while applying serial testing for risk stratification
and (long-term) monitoring of HF patients. Analyses of
NT-proBNP and BNP in HFrEF patients who participated
in the PARADIGM-HF study revealed that NT-proBNP de-
creases on treatment with sacubutril-valsartan, reflecting re-
duced cardiac wall stress, while BNP increases, reflecting
drug action [25]. However, the relative increases in BNP
concentrations in that randomised study were small (me-
dian baseline BNP value approximately 200pg/ml to a me-
dian of about 225pg/ml in the sacubitril-valsartan arm at
8-month follow-up).
Furthermore, it is unlikely that small increments of BNP
on that drug will interfere with the diagnostic applications
of BNP in patients with acute or decompensated heart fail-
ure, usually associated with large increments of BNP.
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Study limitations
The present analysis was observational in design and is
therefore only hypothesis-generating. In the current retro-
spective analysis of a randomised controlled trial, we only
included medical therapy at hospital discharge. In that way,
modifications in the drug treatment and non-pharmacologi-
cal therapy during follow-up were not accounted for in our
analysis. The COACH study was powered for the primary
composite endpoint, time to hospitalisation for HF or all-
cause mortality, but not for the separate, secondary endpoint
all-cause mortality.
Also, the COACH study was conducted at a time when
not all currently recommended drugs for chronic HF were
used and use of device therapy has also markedly increased
since then, which may have affected our findings [12, 26].
Conclusions
Plasma concentrations of both BNP and NT-proBNP at dis-
charge after hospitalisation for HF are equally strong and
independent predictors of all-cause death and HF rehospi-
talisation.
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